Quantum BioPharma Provides Corporate Update
The FDA placed a clinical hold on Quantum BioPharma’s IND for Lucid-MS, its lead multiple sclerosis candidate, pending submission of additional information. The company withdrew all previously disclosed timelines for Phase 2 trial initiation and interim data milestones, citing the need to address the agency’s comments. Dr. Lakshmi P.
Key figures
- Drug Name
- Lucid-21-302 (Lucid-MS)
- Royalty cap
- $250 million
- Ownership unbuzzd
- 19.84%
- Royalty rate initial
- 7%
- Royalty rate post cap
- 3%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.